{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T14:37:50Z","timestamp":1725460670256},"reference-count":19,"publisher":"American Institute of Mathematical Sciences (AIMS)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.3934\/publichealth.2019.4.477","type":"journal-article","created":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:37:35Z","timestamp":1573519055000},"page":"477-487","source":"Crossref","is-referenced-by-count":8,"title":["Low dose oral beta-lactamase protects the gut microbiome from oral beta-lactam-mediated damage in dogs"],"prefix":"10.3934","volume":"6","author":[{"given":"Sheila","family":"Connelly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"1 Synthetic Biologics, Inc., Rockville, MD, United States","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Fanelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nur","family":"A. Hasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"R. Colwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Kaleko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"2 CosmosID, Inc., Rockville, MD, United States","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"3 University of Maryland Institute for Advanced Computer Studies, College Park, MD, United States","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2321","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI78366","article-title":"The microbiome revolution","author":"Blaser MJ","journal-title":"<em>J Clin Invest<\/em>"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1016\/j.anaerobe.2016.05.015","article-title":"Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection","author":"Kaleko M, Bristol JA, Hubert S, et al.","journal-title":"<em>Anaerobe<\/em>"},{"key":"3","unstructured":"3.  Kokai-Kun JF, Roberts T, Coughlin O, et al. (2017) The oral \u03b2-lactamase SYN-004 (ribaxamase) degrades ceftriaxone excreted into the intestine in phase 2a clinical studies. Antimicrob. <em>Agents Chemother<\/em> 61: e02197\u201316.","article-title":"The oral \u03b2-lactamase SYN-004 (ribaxamase) degrades ceftriaxone excreted into the intestine in phase 2a clinical studies"},{"key":"4","unstructured":"4.  Kokai-Kun J, Connelly S (2019) Ribaxamase, an Orally Administered \uf062-lactamase, Protects the Gut Microbiome in Patients Treated with Ceftriaxone. <em>J Transl Sci<\/em> 6: 1\u20139.","article-title":"Ribaxamase, an Orally Administered \uf062-lactamase, Protects the Gut Microbiome in Patients Treated with Ceftriaxone"},{"key":"5","unstructured":"5. Clinicaltrials.gov (2018) A study of SYN-004 for the prevention of <em>C. diff<\/em> in patients with a LRTI. NCT02563106,  September  29,  2015  ed.  Available  from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02563106?term=NCT02563106&amp;recrs=e&amp;draw=2&amp;rank=1.","article-title":"A study of SYN-004 for the prevention of <em>C"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30731-X","article-title":"Use of ribaxamase (SYN-004), a beta-lactamase, to prevent Clostridium difficile infection in beta-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial","author":"Kokai-Kun JF, Roberts T, Coughlin O, et al.","journal-title":"<em>Lancet Infect Dis<\/em>"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms7050150","article-title":"Oral Beta-Lactamase Protects the Canine Gut Microbiome from Oral Amoxicillin-Mediated Damage","author":"Connelly S, Fanelli B, Hasan NA, et al.","journal-title":"<em> Microorg<\/em>"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.5001\/omj.2010.25","article-title":"Colon targeted drug delivery systems: a review on primary and novel approaches","author":"Philip AK, Philip B","journal-title":"<em>Oman Med J<\/em>"},{"key":"9","unstructured":"9. Connelly S, Fanelli B, Hasan NA, et al. (2019) Oral beta-lactamase protects the gut microbiome from damage caused by oral amoxicillin\/clavulanate without interfering with amoxicillin systemic absorption in dogs. <em>Unpublished data<\/em> [In press].","article-title":"Oral beta-lactamase protects the gut microbiome from damage caused by oral amoxicillin\/clavulanate without interfering with amoxicillin systemic absorption in dogs"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-016-0420-0","article-title":"Tolerability and Pharmacokinetics of SYN-004, an Orally Administered beta-Lactamase for the Prevention of Clostridium difficile-Associated Disease and Antibiotic-Associated Diarrhea, in Two Phase 1 Studies","author":"Roberts T, Kokai-Kun JF, Coughlin O, et al.","journal-title":"<em>Clin Drug Investig<\/em>"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2017.10.001","article-title":"Formulation development of SYN-004 (ribaxamase) oral solid dosage form, a beta-lactamase to prevent intravenous antibiotic- associated dysbiosis of the colon","author":"Bristol A, Hubert S, Hofmann F, et al.","journal-title":"<em>Int J Pharm<\/em>"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1002\/j.1538-7305.1948.tb01338.x","article-title":"A mathematical theory of communication","author":"Shannon CE","journal-title":"<em>Bell Syst Tech J<\/em>"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-11-367","article-title":"A flexible R package for nonnegative matrix factorization","author":"Gaujoux R, Seoighe C","journal-title":"<em>BMC Bioinf<\/em>"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1016\/j.scitotenv.2012.10.092","article-title":"Lower-dose prescribing: minimizing \"side effects\" of pharmaceuticals on society and the environment","author":"Daughton CG, Ruhoy IS","journal-title":"<em>Sci Total Environ<\/em>"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-018-0450-3","article-title":"Similarity of the dog and human gut microbiomes in gene content and response to diet","author":"Coelho LP, Kultima JR, Costea PI, et al.","journal-title":"<em>Microbiome<\/em>"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2018.12.047","article-title":"Heat-killed lactobacilli alter both microbiota composition and behaviour","author":"Warda AK, Rea K, Fitzgerald P, et al.","journal-title":"<em>Behav Brain Res<\/em>"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6941.2009.00808.x","article-title":"Changes in fecal microbiota of healthy dogs administered amoxicillin","author":"Gronvold AM, L'Abee-Lund TM, Sorum H, et al.","journal-title":"<em>FEMS Microbiol Ecol<\/em>"},{"key":"18","unstructured":"18. Allaker RP (2012) Non-sporing anaerobes. In: Greenword D, Slack R, Barer M, et al. editor. <em>Medical Microbiology,<\/em>18Eds., Churchill Livingston, 359\u2013364.","article-title":"Non-sporing anaerobes"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1002\/ecs2.2100","article-title":"How robust are popular beta diversity indices to sampling error","author":"Schroeder PJ, Jenkins DG","journal-title":"<em>Ecosphere<\/em>"}],"container-title":["AIMS Public Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.aimspress.com\/article\/10.3934\/publichealth.2019.4.477","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:37:38Z","timestamp":1573519058000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.aimspress.com\/article\/10.3934\/publichealth.2019.4.477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.3934\/publichealth.2019.4.477","relation":{},"ISSN":["2327-8994"],"issn-type":[{"type":"print","value":"2327-8994"}],"subject":[],"published":{"date-parts":[[2019]]}}}